AFP and hepatocellular carcinoma: REACH-2 is the first positive phase 3 trial in patients with HCC performed in a biomarker-selected patient cohort and more recent findings demonstrated that AFP-enriched HCCs displayed significant activation of VEGF which suggests the underlying mechanism of action and confirms the potential value of biomarker-driven clinical trials.123